Avior Wealth Management LLC Buys 268 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Avior Wealth Management LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,190 shares of the biopharmaceutical company’s stock after acquiring an additional 268 shares during the period. Avior Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $848,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the stock. State Street Corp raised its position in Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after acquiring an additional 61,277 shares during the period. International Assets Investment Management LLC raised its position in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after acquiring an additional 879,916 shares during the period. Charles Schwab Investment Management Inc. raised its position in Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after acquiring an additional 11,499 shares during the period. The Manufacturers Life Insurance Company raised its position in Regeneron Pharmaceuticals by 0.7% in the second quarter. The Manufacturers Life Insurance Company now owns 340,566 shares of the biopharmaceutical company’s stock worth $357,945,000 after acquiring an additional 2,270 shares during the period. Finally, Swiss National Bank raised its position in Regeneron Pharmaceuticals by 0.6% in the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock worth $338,079,000 after acquiring an additional 2,000 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on REGN shares. Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Wolfe Research started coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Evercore ISI lowered their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Finally, Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $675.79 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a one year low of $666.25 and a one year high of $1,211.20. The stock has a market cap of $74.26 billion, a PE ratio of 16.72, a P/E/G ratio of 1.59 and a beta of 0.10. The firm has a 50 day simple moving average of $728.81 and a two-hundred day simple moving average of $940.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.